• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revascularization, a c...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Becoming A Hosehead: Sleeping My Way To Better Health
CPAP machines are in the news this month after the New England Journal of Medicine released a study casting doubt on their effectiveness in preventing heart problems. See here for an explanation of the study and a summary of reasons why it is likely not accurate. Regardless of that study, let me tell you why I have become an unexpected missionary for the wonders of the CPAP. For the past year, I've been wrestling with a diagnosis of sleep apnea. What have I learned, even while kicking, screaming and denying, through the entire testing and education process? That it is a real thing, that I really do have it, and that I fee...
Source: Healthy Living - The Huffington Post - September 7, 2016 Category: Consumer Health News Source Type: news